Inactive Instrument

Asterias Biotherapeutics Inc Share Price OTC Bulletin Board

US04624N1072

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

Press Releases: Asterias Biotherapeutics Inc

24/19/24	Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury	GL
10/18/10	Asterias Biotherapeutics Reports Third Quarter Results	GL
08/18/08	Asterias Biotherapeutics : BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company	BU
08/18/08	Asterias Biotherapeutics : BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update	BU
01/18/01	Asterias Biotherapeutics Announces Facilities and IP License Option Agreements	GL

More press releases

News in other languages: Asterias Biotherapeutics Inc

08/14/08

ThyssenKrupp : ECHO BONDS : Fitch relève la perspective de ThyssenKrupp à stable

More news

Managers and Directors: Asterias Biotherapeutics Inc

Manager	Title	Age	Since
Brian Culley CEO	Chief Executive Officer	54	08/03/2019
Jill Howe DFI	Director of Finance/CFO	50	-
George Samuel SEC	Corporate Secretary	45	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.81%	+3.11%	+1.85%	+29.20%	4.63TCr
IQVIA HOLDINGS INC.	+0.86%	+1.78%	+42.30%	+29.70%	4.39TCr
REVOLUTION MEDICINES, INC.	+1.41%	-6.29%	+338.56%	+542.28%	4.09TCr
BEONE MEDICINES AG	+2.32%	+1.25%	+4.92%	+81.93%	3.99TCr
CELLTRION, INC.	-0.50%	+0.67%	+10.29%	+41.57%	2.95TCr
MEDPACE HOLDINGS, INC.	+0.21%	+4.22%	+22.81%	+140.41%	1.71TCr
ASCENDIS PHARMA A/S	+0.82%	-10.17%	-	-	1.55TCr
EUROFINS SCIENTIFIC SE	+1.75%	+7.90%	+24.22%	+40.85%	1.52TCr
TEMPUS AI, INC.	+0.85%	+31.91%	-11.79%	-	1.4TCr
Average	+1.08%	+3.76%	+54.14%	+129.42%	2.92TCr
Weighted average by Cap.	+1.08%	+1.87%	+68.43%	+139.04%

See all sector performances

Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Employees

Sector

Biotechnology & Medical Research

More about the company